Lyell Immunopharma, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
LYEL$16.75+8.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(24,153) | $(52,195) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 4,295 | 6,024 |
| Depreciation and amortization expense | 2,332 | 3,441 |
| Non-cash lease income | (1,100) | (710) |
| Net amortization and accretion on marketable securities | (886) | (1,725) |
| Change in fair value of success payment liabilities | (353) | (125) |
| Gain on securities purchase agreement put/call | (17,561) | — |
| Loss on property and equipment disposals, net | — | 1,291 |
| Change in fair value of contingent consideration payable | — | (1,211) |
| Loss on marketable equity security | — | 26 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current assets and other assets | 90 | 2,000 |
| Accounts payable | 2,383 | (1,654) |
| Accrued liabilities and other current liabilities | (3,567) | (9,788) |
| Other non-current liabilities | 10 | (112) |
| Net cash used in operating activities | (38,510) | (54,738) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchases of property and equipment | (89) | (246) |
| Purchases of marketable securities | (37,183) | (84,411) |
| Maturities of marketable securities | 54,650 | 154,123 |
| Net cash provided by investing activities | 17,378 | 69,466 |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from securities purchase agreement equity issuance | 50,000 | — |
| Proceeds from at-the-market offering, net of offering expenses | 1,696 | — |
| Proceeds from exercise of stock options | 26 | — |
| Taxes paid related to net share settlement of equity awards | — | 1 |
| Net cash provided by financing activities | 51,722 | 1 |
| Net increase in cash, cash equivalents and restricted cash | 30,590 | 14,729 |
| Cash, cash equivalents and restricted cash at beginning of period | 61,766 | 107,287 |
| Cash, cash equivalents and restricted cash at end of period | $92,356 | $122,016 |
| Represented by: | ||
| Cash and cash equivalents | $90,770 | $120,328 |
| Restricted cash | 1,586 | 1,688 |
| Total | $92,356 | $122,016 |
| SUPPLEMENTAL CASH FLOW INFORMATION | ||
| Cash paid for amounts included in the measurement of lease liabilities | $3,186 | $3,095 |
| Non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $192 | $155 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.